SISSA Start-up Borea Therapeutics launches with seed investment from Sofinnova Partners

Borea therapeutics, a biotech start-up based in Milan, received initial funding from Sofinnova Telethon, the largest Italian fund dedicated to the financing of innovative biotechnology. Borea is developing next-generation adenoviral vectors specifically targeted to the central and peripheral nervous system for gene therapy. The company was founded in 2020 by Paul Heppenstall, a full professor at SISSA, and European Molecular Biology Laboratory - EMBL. The company’s research activities are done in cooperation with SISSA.

Read the press release here.